Exhibit 99.1

 MEDICOR LTD. AND BIOSIL LIMITED AND NAGOR LIMITED ANNOUNCE ANTICIPATED CLOSING
                            SCHEDULE FOR ACQUISITION

    LAS VEGAS, Jan. 18 /PRNewswire-FirstCall/ -- Las Vegas-based MediCor Ltd.
(OTC Bulletin Board: MDCR) and British breast implant manufacturer Biosil
Limited and supplier Nagor Limited announced today that they have agreed to
schedule the closing of MediCor's acquisition of Biosil and Nagor for the second
quarter of 2006.

    According to MediCor's Chief Operating Officer, Jim J. McGhan, "The parties
are actively working toward a successful close. We are also pleased by the
British Association of Aesthetic Plastic Surgeons (BAAPS) report that the U.K.
experienced an approximate 51% increase in breast implant procedures in 2005, a
market in which Nagor has a significant market presence. In addition to the
U.K., Nagor also has a solid base of highly qualified international distribution
partners worldwide. Given the dynamic market growth and distributor network
already in place, we are anxious to begin building upon the current Biosil and
Nagor employee bases and expanding operations in the Scotland, England and the
Isle of Man facilities to meet future demand."

    MediCor was founded by Chairman of the Board Donald K. McGhan, the pioneer
of the modern day breast implant industry. The Company acquires, develops,
manufactures and markets products for medical specialties in aesthetic, plastic
and reconstructive surgery and dermatology markets. Products include surgically
implantable prostheses for aesthetic, plastic and reconstructive surgery and
scar management products. Its products are sold worldwide to hospitals, surgery
centers and physicians through various distributors and direct sales personnel.
MediCor's strategy is to be the leading integrator of selected international
medical device markets, technologies and corporations. To achieve this strategy,
MediCor intends to build upon and expand its business lines, primarily in the
aesthetic, plastic and reconstructive surgery and dermatology markets. MediCor
intends to accomplish this growth through the expansion of existing product
lines and offerings and through the acquisition of companies and other assets,
including intellectual property rights or distribution rights.

    This release may contain forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such statements are based
upon the current beliefs and expectations of MediCor's management and are
subject to significant risks and uncertainties. Actual results may differ from
those set forth in the forward-looking statements.

    The following factors, among others, could cause actual results to differ
from those set forth in the forward-looking statements: the ability to obtain
requisite financing, the risk of instability in the capital markets in the U.S.
and internationally, the ability to obtain governmental approvals of the
transactions; the ability to satisfy any agreed closing conditions; the risk of
the occurrence of material adverse changes in the business or financial
conditions of the companies; the risk that the businesses will not be integrated
successfully; the risk that cost savings from acquisition transactions may not
be realized or may take longer to realize than expected; disruption from
transactions making it more difficult to maintain relationships with customers,
employees or suppliers; increased competition and its effect on pricing,
spending, third-party relationships and revenues; the outcome of certain
political and legal proceedings; the risk of new and changing regulations in the
U.S. and internationally. Additional factors that could cause MediCor's results
to differ materially from those described in the forward-looking statements can
be found in the Annual Report on Form 10-KSB for the year ended June 30, 2005,
and subsequent Quarterly Reports on Form 10-QSB of MediCor filed with the
Securities and Exchange Commission and available at the Securities and Exchange
Commission's Internet site (http://www.sec.gov).

SOURCE  MediCor Ltd.
    -0-                             01/18/2006
    /CONTACT:  Marc S. Sperberg, U.S., +1-702-932-4568, for MediCor Ltd./
    (MDCR)